Evidation Health

Evidation operates a real-world data platform that connects directly with individuals to collect continuous, longitudinal, patient-level health data. The data it assembles spans clinical data (EHR and claims), demographic and social context, condition and treatment experience, patient-reported outcomes, molecular data from biosamples, and digital measures from wearables. The company positions this combination as providing temporal depth beyond conventional real-world data, which it characterizes as largely reflecting discrete clinical encounters rather than how patients manage conditions and experience treatment between visits.

On the life sciences side, Evidation supports research, discovery and early development; evidence generation and medical value; and commercial planning and market strategy. It maintains more than 20 condition-specific data collection cohorts, with named focus areas in cardiometabolic health (including weight journeys and GLP-1 use), autoimmune disease (flares, symptom burden, disease progression) and dermatology (symptoms, treatment, care pathways and outcomes).

On the individual side, Evidation runs a consumer app through which people choose to share health data with researchers, receive personalized insights and earn rewards, retaining control over what is shared, with whom and for how long. The company describes its foundation as privacy-first and consent-based.

Business model

Evidation operates a two-sided model: it recruits and engages individuals through its app, offering personalized insights and monetary rewards in what it describes as a consented mutual value exchange, and provides the resulting longitudinal, multimodal real-world data and insights to life sciences organizations for research, evidence generation and commercial decision-making.

Traction

The company reports 5 million individuals participating in its community across 97% of U.S. ZIP codes, more than 1 million people helped to participate in research, over 20 condition-specific cohorts, 140+ real-world studies supported on its platform, 100+ peer-reviewed publications led or supported, partnerships with 90% of the top biopharma companies, and millions of dollars paid out in participant rewards.

Latest developments

Recent activity includes the appointment of Leslie Oley Wilberforce as CEO and Dr. Ghazanfar Khan as Chief Medical Officer; the launch of an AI-enabled temporal proteomics platform for autoimmune research; the launch of an interactive dermatology cohort; and the publication of real-world GLP-1 insights drawn from cardiometabolic and weight-management cohorts of 60,000 to 165,000 individuals.